Clinical Trial Update: Study of Ipilimumab and Dasatinib Combination Therapy in Patients With Chronic or Accelerated Chronic Myeloid Leukemia [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating the combination of ipilimumab and dasatinib in patients with chronic or accelerated chronic myeloid leukemia has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Accelerated-phase Chronic Myeloid Leukemia
• Chronic Myeloid Leukemia

Drugs mentioned

• DASATINIB (Dasatinib)
• ipilimumab (ipilimumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Leukemia, Myeloid, Chronic | Phase 1 | Status: WITHDRAWN